TrialArthritis research & therapy2015

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.

Michael E Weinblatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.